Khuri FR - Search Results

1

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.

Hitosugi T, Zhou L, Fan J, Elf S, Zhang L, Xie J, Wang Y, Gu TL, Alečković M, LeRoy G, Kang Y, Kang HB, Seo JH, Shan C, Jin P, Gong W, Lonial S, Arellano ML, Khoury HJ, Chen GZ, Shin DM, Khuri FR, Boggon TJ, Kang S, He C, Chen J. Hitosugi T, et al. Among authors: khuri fr. Nat Commun. 2013;4:1790. doi: 10.1038/ncomms2759. Nat Commun. 2013. PMID: 23653202 Free PMC article.

2

Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Shin DM, Glisson BS, Khuri FR, Hong WK, Lippman SM. Shin DM, et al. Among authors: khuri fr. Semin Oncol. 1998 Apr;25(2 Suppl 4):40-4; discussion 45-8. Semin Oncol. 1998. PMID: 9578061 Clinical Trial.

3

Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.

Khuri FR, Shin DM, Glisson BS, Lippman SM, Hong WK. Khuri FR, et al. Semin Oncol. 2000 Aug;27(4 Suppl 8):25-33. Semin Oncol. 2000. PMID: 10952435 Review.

4

Recent advances in the management of squamous cell carcinoma of the head and neck.

Kim KB, Khuri FR, Shin DM. Kim KB, et al. Among authors: khuri fr. Expert Rev Anticancer Ther. 2001 Jun;1(1):99-110. doi: 10.1586/14737140.1.1.99. Expert Rev Anticancer Ther. 2001. PMID: 12113140 Review.

5

Emerging drugs for head and neck cancer.

Rhee JC, Khuri FR, Shin DM. Rhee JC, et al. Among authors: khuri fr. Expert Opin Emerg Drugs. 2004 May;9(1):91-104. doi: 10.1517/eoed.9.1.91.32953. Expert Opin Emerg Drugs. 2004. PMID: 15155138 Review.

6

Advances in chemoprevention of head and neck cancer.

Rhee JC, Khuri FR, Shin DM. Rhee JC, et al. Among authors: khuri fr. Oncologist. 2004;9(3):302-11. doi: 10.1634/theoncologist.9-3-302. Oncologist. 2004. PMID: 15169985 Free article. Review.

7

Prevention of head and neck cancer: current status and future prospects.

Jain S, Khuri FR, Shin DM. Jain S, et al. Among authors: khuri fr. Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86. doi: 10.1016/j.currproblcancer.2004.05.003. Curr Probl Cancer. 2004. PMID: 15375804 Review. No abstract available.

8

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S. David E, et al. Among authors: khuri fr. Blood. 2005 Dec 15;106(13):4322-9. doi: 10.1182/blood-2005-06-2584. Epub 2005 Aug 23. Blood. 2005. PMID: 16118318 Free article.

9

Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.

Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR, Shin DM. Zhang X, et al. Among authors: khuri fr. Clin Cancer Res. 2005 Sep 1;11(17):6261-9. doi: 10.1158/1078-0432.CCR-04-2102. Clin Cancer Res. 2005. PMID: 16144930

10

Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.

Saba NF, Khuri FR, Shin DM. Saba NF, et al. Among authors: khuri fr. Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim. Oncology (Williston Park). 2006. PMID: 16562649 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

496 results

Search Page

Filters